A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

Autor: Amandine Le Bourgeois, Marion Eveillard, Camille Debord, Joëlle Gaschet, Marie-C. Béné, Cyrille Touzeau, Soraya Wuilleme, Michel Chérel, Thierry Guillaume, Thomas Gastinne, Patrice Chevallier, Philippe Moreau, Catherine Godon, Benoit Tessoulin, Beatrice Mahe, Olivier Theisen, Nicolas Blin, Alice Garnier, Viviane Dubruille, Anne Lok, Pierre Peterlin, Yannick Le Bris, Steven Le Gouill
Přispěvatelé: Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre hospitalier universitaire de Nantes (CHU Nantes), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), CRLCC René Gauducheau, Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Bernardo, Elizabeth
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
Response to therapy
medicine.medical_treatment
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
prognostic biomarker
Original Research
Potential impact
biology
Myeloid leukemia
Induction Chemotherapy
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Pathophysiology
3. Good health
Survival Rate
Leukemia
Myeloid
Acute
Cytokine
030220 oncology & carcinogenesis
Female
Adult
medicine.medical_specialty
Induction Phase
[SDV.CAN]Life Sciences [q-bio]/Cancer
acute myeloid leukemia
lcsh:RC254-282
03 medical and health sciences
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
medicine
Biomarkers
Tumor
Humans
FLT3 ligand
Radiology
Nuclear Medicine and imaging
Interleukin 6
Aged
IL-6
business.industry
Interleukin-6
Clinical Cancer Research
Membrane Proteins
IL‐6
030104 developmental biology
biology.protein
business
Intermediate risk
Follow-Up Studies
Zdroj: Cancer Medicine, Vol 10, Iss 2, Pp 642-648 (2021)
Cancer Medicine
Cancer Medicine, Wiley, 2021, 10 (2), pp.642-648. ⟨10.1002/cam4.3648⟩
Cancer Medicine, 2021, 10 (2), pp.642-648. ⟨10.1002/cam4.3648⟩
ISSN: 2045-7634
Popis: The aim of this study was to assess the potential impact of the kinetics of serum levels of seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, the role of cytokines, in the pathophysiology and response to therapy of AML patients, remains under investigation. Here, we report on the impact of peripheral levels of two cytokines, the Fms‐like tyrosine kinase 3 ligand (FL) and interleukin‐6 (IL‐6), evaluated during first‐line intensive induction. A new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining the kinetic profile of these cytokines during the induction phase. It segregates three groups of, respectively, high‐risk, characterized by a stagnation of low FL levels, intermediate risk, with dynamic increasing FL levels and high IL‐6 at day 22, and favorable risk with increasing FL levels but low IL‐6 at day 22.
Here we report on the impact of the peripheral levels of two cytokines, the Fms‐like tyrosine kinase 3 ligand (FL), and interleukin‐6 (IL‐6), evaluated during first‐line intensive induction. Indeed, a new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining their profile during the induction phase.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje